CompletedNot Applicable

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

China1,001 participantsStarted 2009-12

Plain-language summary

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered. Exclusion Criteria: * Contraindications stated in the local Moxifloxacin product information. Warnings and precautions, stated in the local Moxifloxacin product information must be considered as potential exclusion criteria.

What they're measuring

Types of cIAI infections

Timeframe: Day 1

Trial details

NCT IDNCT01096511

SponsorBayer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2011-01

View on ClinicalTrials.gov More Secondary Peritonitis trials